Pursuant to Regulation 47 of SEBI (LODR) Regulations, 2015, please find enclosed herewith Newspaper Publication on Unaudited (Standalone and Consolidated) Financial Results for the Quarter ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gennex Laboratories has submitted newspaper copies of its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, as published in Business Standard and Saksham on November 16–17, 2025. Standalone total income from operations rose to Rs 3,136.81 lakh in Q2 FY26 from Rs 2,651.03 lakh in Q2 FY25, up about 18% year-on-year. Standalone net profit after tax grew to Rs 453.82 lakh from Rs 415.85 lakh, while EPS stood at Rs 0.187 versus Rs 0.189 earlier. On a consolidated basis, H1 FY26 net profit after tax was Rs 1,052.80 lakh versus Rs 1,002.98 lakh in H1 FY25. The results were approved by the Board at its meeting held on November 14, 2025.
The company showed healthy revenue growth in Q2 with marginally improved profitability, but EPS dipped slightly YoY due to a higher equity base (Rs 2,429.48 lakh vs Rs 2,274.48 lakh), suggesting a possible equity issuance. For retail shareholders, this is a routine compliance disclosure with no major surprise, though the steady growth is mildly positive.